cmAngio® vs iPredict Eye Screening
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your radiology, women's health, or cardiology practice aims to enhance cardiovascular risk assessment by leveraging existing mammography images. This AI software is ideal for identifying Breast Arterial Calcifications (BAC) without requiring additional patient procedures or radiation, providing valuable insights into a woman's cardiovascular health during routine breast screenings.
View cmAngio® →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your primary care, internal medicine, or ophthalmology clinic seeks a comprehensive and rapid AI-powered screening solution for multiple eye diseases, including AMD, DR, and Glaucoma. This tool is also well-suited for providing early risk prediction for systemic conditions like stroke and heart attack, integrating seamlessly into a quick, non-invasive patient workflow.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | iPredict Eye Screening |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact for pricing |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B emphasizes an easy-to-operate, non-invasive, advanced touchscreen interface with fast test completion (under 5 minutes) and report generation (under 60 seconds), suggesting a highly streamlined user experience for direct patient screening. Tool A focuses on quick installation and compatibility with existing DICOM viewers, which is good for integration, but Tool B's direct patient interaction and speed give it an edge in overall usability for a broader range of clinical settings.
Clinical Value
iPredict Eye ScreeningTool B offers a broader clinical impact by providing FDA-cleared AI-powered screening for multiple prevalent eye diseases (Diabetic Retinopathy, Age-related Macular Degeneration, Glaucoma) and includes risk prediction for systemic diseases like stroke and heart attack, with stated high accuracy. Tool A, while valuable, focuses on a single indicator (Breast Arterial Calcifications) for cardiovascular risk from mammograms.
Pricing & Value
iPredict Eye ScreeningTool B provides a more transparent pricing model, detailing a per-patient screening Software as a Service (SaaS) model with an estimated cost range. This allows potential customers to better understand and budget for the service. Tool A's pricing information is not publicly available, making it difficult to assess its value proposition without direct vendor contact.
Enterprise Readiness
iPredict Eye ScreeningBoth tools are FDA-cleared, HIPAA-compliant, and cloud-based. However, Tool B explicitly highlights Electronic Health Record (EHR) Solutions and accessibility in diverse settings including primary care, clinics, hospitals, and telemedicine, indicating a more comprehensive approach to enterprise integration. Tool A's DICOM compatibility is strong for radiology workflows, but Tool B's broader integration points suggest greater readiness for varied healthcare environments.
Innovation
iPredict Eye ScreeningTool B demonstrates a wider scope of innovation by integrating AI for multiple disease screenings, systemic risk prediction, and an AI-based telemedicine service, extending beyond just image analysis to a more comprehensive diagnostic and predictive platform. Tool A's innovation in repurposing mammography data for cardiovascular risk is significant, but Tool B's multi-faceted approach and integration with telemedicine represent a broader innovative footprint.
Support & Docs
TieBased on the provided structured facts and web search results, neither tool explicitly details public support portals, comprehensive documentation libraries, or specific service level agreements. Both companies offer general contact information for inquiries.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | iPredict Eye Screening |
|---|---|---|
| Tool Name | cmAngiou00ae | iPredict Eye Screening |
| Company | CureMetrix | iHealthScreen |
| Primary Function | Detecting Breast Arterial Calcifications (BAC) on mammograms | AI-powered screening for age-related macular degeneration (AMD), Diabetic Retinopathy (DR), and Glaucoma |
| Key Feature 1 | AI-based detection of Breast Arterial Calcifications (BAC) | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma |
| Key Feature 2 | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Electronic Health Record (EHR) Solutions |
| Key Feature 3 | Provides visualization of BAC location on a scorecard | AI-Based Telemedicine Service |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and iPredict Eye Screening.